MIRA MIRA PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1904286
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY100.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-135.7%
ROA-131.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.9%
Debt / equity0.00x
Current ratio16.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-66.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $1.72M | $3.31M |
| SG&A expense | $8.77M | $4.71M |
| Interest expense | — | -$165,669 |
| Net income | -$10.44M | -$7.85M |
| EPS (basic) | -1.35 | -0.51 |
| EPS (diluted) | -1.35 | -0.51 |
| Weighted avg. shares (diluted) | — | 15.44M |
| Banking | ||
| Net interest income | $98,911 | $165,669 |
| Balance sheet | ||
| Cash & equivalents | $6.35M | $2.83M |
| Short-term investments | $4.68M | — |
| Current assets | $11.06M | $2.89M |
| Total assets | $11.09M | $2.92M |
| Current liabilities | $702,068 | $723,349 |
| Total liabilities | $702,068 | $723,349 |
| Shareholders' equity | $10.39M | $2.20M |
| Shares outstanding | 41.94M | 16.56M |
| Cash flow statement | ||
| Operating cash flow | -$4.66M | -$5.56M |
| Financing cash flow | $8.18M | $3.79M |
| Stock-based compensation | $6.31M | $1.92M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.